Abstract
BackgroundArmed monoclonal antibody (mAb)-based therapeutics, e.g., antibody-drug conjugates (ADCs) or antibody-oligonucleotide conjugates (AOCs), can be highly effective for patients with gene-amplified or protein-overexpressing tumors. However, many tumor cells do not...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
